戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rs, WHO performance status of 2, or elevated serum lactate dehydrogenase).
2 nced-stage disease, B symptoms, and elevated serum lactate dehydrogenase.
3 ted closely with hemolysis, as determined by serum lactate dehydrogenase.
4 s, abnormal cytogenetics, and high levels of serum lactate dehydrogenase and beta(2)-microglobulin as
5 te count, disease stage, performance status, serum lactate dehydrogenase, and number of extranodal si
6  deletion or 11q deletion by FISH, increased serum lactate dehydrogenase, and unmutated IGHV mutation
7                                          The serum lactate dehydrogenase concentrations and the alveo
8 ow Karnofsky performance status (<80%), high serum lactate dehydrogenase (&gt; 1.5 times upper limit of
9  thrombocytopenia (<20,000/microl), elevated serum lactate dehydrogenase (&gt;1,500U/liter), schistocyto
10 oliferation and apoptosis markers as well as serum lactate dehydrogenase isoenzyme 1 (S-LD-1) may hav
11  opportunistic pneumonia had a higher median serum lactate dehydrogenase (LDH) concentration than did
12  these patients were median age of 56 years; serum lactate dehydrogenase (LDH) greater than 1N, 60%;
13                Tumor burden was estimated by serum lactate dehydrogenase (LDH) measurement and reclas
14 seen even in the elderly, in those with high serum lactate dehydrogenase (LDH) or beta2-microglobulin
15 ion after CD138 plasma cell purification and serum lactate dehydrogenase (LDH) to evaluate their prog
16                       Importantly, increased serum lactate dehydrogenase (LDH) was identified as an a
17     RT-PCR results were also correlated with serum lactate dehydrogenase (LDH), treatment status, and
18  status, liver metastases, disease site, and serum lactate dehydrogenase (LDH).
19 ity and markers of hemolysis, in particular, serum lactate dehydrogenase (LDH).
20 uded WHO performance status (0 v 1 or 2) and serum lactate dehydrogenase (LDH; </= v > 1.5x the upper
21               No parameters (eg, age, stage, serum lactate dehydrogenase [LDH], beta(2) microglobulin
22 riable and multivariable analysis, increased serum lactate dehydrogenase level and histology for a me
23             Multivariate analysis identified serum lactate dehydrogenase level and the NOTCH1/FBXW7/R
24                            The pretransplant serum lactate dehydrogenase level was the most important
25 n had poor-risk features defined as elevated serum lactate dehydrogenase level, stage IV, and bulky m
26 ltivariate analysis including M substage and serum lactate dehydrogenase level.
27 r visceral metastatic sites) and an elevated serum lactate dehydrogenase level.
28 osis, a decrease in hematocrit, and elevated serum lactate dehydrogenase levels were observed.
29 n Arbor stage IV, low serum albumin and high serum lactate dehydrogenase levels.
30                    In patients with elevated serum lactate dehydrogenase (n = 84), median PFS and OS
31 e frequent in patients with normal levels of serum lactate dehydrogenase, no bone marrow involvement,
32 btype, and correlated with disease stage and serum lactate dehydrogenase (R(s) = 0.79, P < .001).
33                                              Serum lactate dehydrogenase was high in 35%, and beta-2

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。